Document:

EX-10.16

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.16 
 AMENDMENT NO. 2 TO THE COLLABORATION AGREEMENT BETWEEN 

Laboratory Corporation of America Holdings 

and 
 Ariosa Diagnostics,
Inc. 
 THIS AMENDMENT (“Amendment”) is effective as of March 25, 2014 (the “Second Amendment Effective
Date”) by and between Laboratory Corporation of America Holdings, a Delaware corporation (“LabCorp”) and ARIOSA Diagnostics, Inc., a Delaware corporation (“ARIOSA”) (hereinafter, each of LabCorp and ARIOSA
a “Party” and, collectively, the “Parties”). 
 WHEREAS, the parties hereto have entered into the
Collaboration Agreement effective May 1, 2012, as amended by an Amendment No. 1 effective March 1, 2014 (as amended, the “Agreement”); and 

WHEREAS, the parties wish to further amend the Agreement as indicated below. 

NOW, THEREFORE, in consideration of the mutual agreements provided below, the Parties agree to amend the Agreement as follows: 

 

	1.	All capitalized terms not otherwise defined in this Amendment have the same meaning as in the Agreement. 

  

	2.	Section 3.1(b) is hereby deleted in its entirety and replaced with the following: 

 The
Parties agree that certain supplies are required to properly order, collect and preserve Harmony Test specimens. Unless otherwise agreed to in writing, for each Harmony Test specimen, ARIOSA shall provide LabCorp with [*] and a Test Requisition Form
during the Term, as provided for in Section 4.1. In order to preserve Harmony Test specimens for shipment, the following materials are required: [*]. The Parties acknowledge and agree that concurrently with the execution of this Second
Amendment, [*]. After the Second Amendment Effective Date, LabCorp will be responsible for obtaining (and paying for) the Preservation Materials and all other costs associated therewith [*]. In either case, LabCorp shall be responsible for providing
all such supplies to LabCorp collection personnel and customers, and shipping patient samples to ARIOSA, all at LabCorp’s sole expense [*] to LabCorp’s locations as described in Section 4.1(b)), as necessary to order and collect the
Harmony Test specimens and provide them to ARIOSA hereunder. 
  

	3.	Section 3.2 is hereby deleted in its entirety and replaced with the following: 

 3.2
Payer Discussions. LabCorp and Ariosa shall each have the right to engage payers and insurers in contracting and reimbursement discussions that relate to the Harmony Test. Each party shall have responsibility for any payer and/or contracting
discussions that relates to its sales of the Harmony Test. 

	4.	In Section 7.1(a), the following sentence is hereby deleted: 

 Following the Exclusive
Period, ARIOSA shall have the exclusive right to alter the List Price, upon [*], to [*]. 
 The sentence referenced immediately above is
hereby replaced with the following: 
 Following the Exclusive Period, each party shall have the right to establish its own List Price and
change such List Price from time to time [*]. 
  

	5.	In the fourth sentence of Section 7.1(b)(i), the following clause is hereby deleted: 

which California Tests shall be paid at the List Price for each California Test that results in a test report generated on behalf of LabCorp
(the “California ARIOSA Fee”). 
 The clause referenced immediately above is hereby replaced with the following: 

which California Tests shall be paid at [*]. 
  

	6.	In the fifth sentence of Section 7.1(b)(i), the words “fifty percent (50%) of the List Price” are hereby replaced with [*]. 

 

	7.	In Section 7.1(b)(ii), the words “(i.e., List Price)” are hereby deleted and replaced with “[*]”. 

  

	8.	In Section 8.3, the following clause at the end of the first sentence is hereby deleted: 

provided, however, ARIOSA may perform any test requested directly by any such customer on the customer’s own initiative, so long as the
Harmony Test is performed at a price not less than the current List Price. 
 The clause referenced immediately above is hereby replaced
with the following: 
 provided, however, during the Non-Solicitation Period ARIOSA may perform any test requested directly by any such
customer on the customer’s own initiative [*]. 
  

  
 2 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

	9.	[*]. 

  

	10.	The terms of this Amendment will become effective on the Second Amendment Effective Date and are irrevocable by either party following execution of this Amendment (without the written agreement of the other party).

 All other terms and conditions of the Agreement remain in full force and effect. 

[SIGNATURES APPEAR ON FOLLOWING PAGE] 

  
 3 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, the Parties have executed this Amendment on the date indicated below,
to be effective as of the Second Amendment Effective Date. 
 LABORATORY CORPORATION OF AMERICA HOLDINGS 

			
		
	By:	 	/s/ Marianne Levandoski
	Name:	 	Marianne Levandoski
	Title:	 	VP
	Date:	 	3-25-2014

 ARIOSA DIAGNOSTICS, INC. 

			
		
	By:	 	/s/ Ken Song
	Name:	 	Ken Song
	Title:	 	CEO
	Date:	 	March 25, 2014

  
 4 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.17

 [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 Exhibit
10.17 
 AMENDMENT NO. 3 TO THE COLLABORATION AGREEMENT BETWEEN 

Laboratory Corporation of America Holdings 

and 
 Ariosa Diagnostics,
Inc. 
 THIS AMENDMENT NO. 3 (the “Amendment”) is effective as of April 4, 2014 (the “Third
Amendment Effective Date”) by and between Laboratory Corporation of America Holdings, a Delaware corporation (“LabCorp”) and ARIOSA Diagnostics, Inc., a Delaware corporation (“ARIOSA”) (hereinafter, each of
LabCorp and ARIOSA a “Party” and, collectively, the “Parties”). 
 WHEREAS, the parties hereto have
entered into the Collaboration Agreement effective May 1, 2012, as amended by Amendment No. 1 effective March 1, 2014 (the “First Amendment”), and Amendment No. 2 effective March 25, 2014 (the
“Second Amendment”) (as amended by the First Amendment and the Second Amendment, the “Agreement”); and 

WHEREAS, the Parties wish to further amend the Agreement to clarify payment and accounting for California Tests, as indicated below.

 NOW, THEREFORE, in consideration of the mutual agreements provided below, the Parties agree to amend the Agreement as follows:

  

	1.	All capitalized terms not otherwise defined in this Amendment have the same meaning as in the Agreement. 

  

	2.	The fourth, fifth, and sixth sentences in Section 7.1(b)(i) are hereby deleted in their entirety and replaced with the following: 

“As to sales in the U.S., LabCorp agrees to remit payment to ARIOSA within [*] after receipt of said statement an amount initially equal
to [*] (the “ARIOSA Subcontract Fee”) [*]. For [*] reported by ARIOSA [*], LabCorp shall remit payment as follows: (1) [*], or (2) [*]. No later than the Third Amendment Effective Date, LabCorp shall provide ARIOSA with a
written accounting of all samples submitted [*]. Such accounting is final and shall indicate with particularity which samples are [*], and shall also include [*]. If LabCorp fails to provide such accounting concurrently with the execution of the
Third Amendment, [*]. To the extent LabCorp has already paid [*]. After the Third Amendment Effective Date, LabCorp shall provide ARIOSA with a monthly accounting indicating [*]. For clarity, the [*] may only be extended by written agreement and
shall not be extended by any re-issues of an invoice [*]. LabCorp and ARIOSA agree that failure to provide such [*]. Notwithstanding the foregoing, in the event that Harmony Tests are (i) repeated at a customer’s request for quality
assurance reasons or verification, (ii) performed solely for research and development and/or validation purposes [*], or (iii) performed without payment as part of a collaboration [*], then the payment that would

 
otherwise be due to ARIOSA shall be [*]. For the avoidance of doubt, notwithstanding anything to the contrary herein, [*] reported by ARIOSA prior to January 1, 2014 shall remain payable as
set forth in the First Amendment [*].” 
  

	3.	The last sentence of Section 7.1(b)(ii) is hereby deleted in its entirety and replaced with the following: 

“For purposes of clarification, all [*] reported by ARIOSA prior to January 1, 2014 shall remain payable pursuant to the First
Amendment [*], and all [*] reported by ARIOSA on or after January 1, 2014 shall be payable at [*], as applicable.” 
  

	4.	Section 7.1(b)(v) is hereby deleted in its entirety and replaced with the following: 

“Upon reasonable written notice and during normal business hours, ARIOSA shall have the right to inspect LabCorp’s books and records
(and those of any LabCorp Affiliates exercising rights under this Agreement) [*], for the purpose of verifying that LabCorp’s compliance with the obligations of this Section 7, including without limitation, for the purpose of examining
(1) LabCorp’s calculation of the Average Reimbursement Rate prior to the First Amendment Effective Date, and (2) the supporting documentation for classifying a [*]. Such audit will be independently conducted by a third party firm with
access to reasonable back-up documentation, and [*]. If such audit reveals that the amounts paid by LabCorp to Ariosa for any period audited represent an underpayment (for example, due to an improper calculation of the Average Reimbursement Rate or
improper classification of a [*], LabCorp shall promptly pay any such shortfalls (and in any event no less than [*] days after the conclusion of the audit). LabCorp will retain all records relating to any charges to its customer, reimbursements, and
any others as necessary to reproduce its accountings under this Section for a period of [*] from the date of such charge, reimbursement or related activity [*].” 
  

	5.	The terms of this Amendment will become effective on the Third Amendment Effective Date and are irrevocable by either party following execution of this Amendment (without the written agreement of the other party).

 All other terms and conditions of the Agreement remain in full force and effect. 

 
  

[SIGNATURES APPEAR ON FOLLOWING PAGE] 
  

 

  
 2 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 IN WITNESS WHEREOF, the Parties have executed this Amendment on the date indicated below, to be effective
as of the Third Amendment Effective Date. 
 LABORATORY CORPORATION OF AMERICA HOLDINGS 

			
		
	By:	 	/s/ Marianne Levandoski

			
		
	Name:	 	Marianne Levandoski

			
		
	Title:	 	VP

			
		
	Date:	 	4-4-2014

 ARIOSA DIAGNOSTICS, INC. 

			
		
	By:	 	/s/ Ken Song

			
		
	Name:	 	Ken Song

			
		
	Title:	 	CEO

			
		
	Date:	 	April 4, 2014

  
 3 

[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange
Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00229-of-00352.parquet"}]]